Adds to existing law to establish provisions regarding limitation of distribution and waiver of immunity for certain human gene therapy products.

The purpose of this legislation is to ensure accountability in the distribution and administration of human gene therapy products for infectious disease indications in Idaho. Given the unique nature of these products which mayhavelong-termandunforeseenconsequences–thisbillestablishesthatmanufacturersmustacceptfulllegal responsibility for design defects in their products if they choose to distribute them in the state. Under current federal law, certain vaccine manufacturers are shielded from liability for design defects through the National Childhood Vaccine Injury Act (42 U.S.C. 300aa-1, et seq.). This bill removes such immunity for human gene therapy products distributed in Idaho, ensuring that manufactures remain legally accountable for potential design defects. By requiring an affirmative waiver of immunity, this legislation prioritizes the rights of Idaho citizens to seek redress for injuries potentially caused by potentially defective human gene therapy products. It also serves as a safeguard against the unchecked proliferation of genetic medical interventions that have not been subjected to adequate long-term study.